Hochschulschrift
Wilms' tumor 1 (WT1) specific immune cells as a tool for cellular immunotherapy in acute myeloid leukemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Duisburg, Essen, Universität Duisburg-Essen, Diss., 2015
- Keyword
-
Krebs
Onkologie
- Event
-
Veröffentlichung
- (where)
-
Duisburg, Essen
- (who)
-
Universitätsbibliothek Duisburg-Essen
- (when)
-
2015
- Creator
- Contributor
-
Lindemann, Monika
Brandau, Sven
- URN
-
urn:nbn:de:hbz:464-20150828-081602-0
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
- Danielzik, Tina
- Lindemann, Monika
- Brandau, Sven
- Universitätsbibliothek Duisburg-Essen
Time of origin
- 2015
Other Objects (12)
WT1 peptide analogue WT1-126Y enhances leukemia lysis
Recent developments in immunotherapy of acute myeloid leukemia
WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target
Natural killer cell-based immunotherapy for acute myeloid leukemia
Acute myeloid leukemia (AML) immunotherapy with genetically programmed dendritic cells
Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies
New insights into antigen specific immunotherapy for chronic myeloid leukemia
An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
Use of cellular immunotherapy for treatment of refractory acute myeloid leukemia
The role of peptide and DNA vaccines in myeloid leukemia immunotherapy
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia
WT1 peptide analogue WT1-126Y enhances leukemia lysis
Recent developments in immunotherapy of acute myeloid leukemia
WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target
Natural killer cell-based immunotherapy for acute myeloid leukemia
Acute myeloid leukemia (AML) immunotherapy with genetically programmed dendritic cells
Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies
New insights into antigen specific immunotherapy for chronic myeloid leukemia
An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
Use of cellular immunotherapy for treatment of refractory acute myeloid leukemia
The role of peptide and DNA vaccines in myeloid leukemia immunotherapy
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia
WT1 peptide analogue WT1-126Y enhances leukemia lysis
Recent developments in immunotherapy of acute myeloid leukemia
WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target
Natural killer cell-based immunotherapy for acute myeloid leukemia
Acute myeloid leukemia (AML) immunotherapy with genetically programmed dendritic cells
Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies
New insights into antigen specific immunotherapy for chronic myeloid leukemia
An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
Use of cellular immunotherapy for treatment of refractory acute myeloid leukemia
The role of peptide and DNA vaccines in myeloid leukemia immunotherapy
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia